Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Oral Surg Oral Med Oral Pathol Oral Radiol ; 117(5): 608-616.e1, 2014 May.
Article in English | MEDLINE | ID: mdl-24603057

ABSTRACT

OBJECTIVE: Ameloblastic carcinoma often poses diagnostic challenges in its separation from benign ameloblastoma with atypical cytologic features or an unusual clinical course. This study aimed to determine whether SOX2 (sex determining region-Y-related high mobility group box 2), a protein expressed in the epithelial basal proliferative zone in dentigerous cysts, is a marker for ameloblastic carcinoma as well as for high-grade transformation in ameloblastic neoplasms. STUDY DESIGN: Immunoperoxidase stains were performed according to a standard protocol. Immunostains were interpreted independently by 3 pathologists, and scores were recorded based on the percentage of staining and intensity of staining in the cells of interest. RESULTS: The diffuse strong nuclear staining pattern has 86.4% specificity (19 of 22) to indicate the presence of high-grade features and has 76.9% sensitivity (10 of 13) in comparison with benign counterparts (P = .0021). Although previously shown as a marker for ameloblastic neoplasms, calretinin is weakly positive in a few cells in 50% (5 of 10) of ameloblastic carcinoma and 43% (3 of 7) of benign ameloblastic neoplasms, with little value in highlighting the high-grade change (P = .36). CONCLUSIONS: The diffuse nuclear staining pattern of SOX2 is suggestive of a high-grade process in ameloblastic neoplasms. Numerous aggregates of cells harboring dense nuclear stain should raise concern for a malignancy.


Subject(s)
Ameloblastoma/metabolism , Biomarkers, Tumor/metabolism , Jaw Neoplasms/metabolism , SOXB1 Transcription Factors/metabolism , Ameloblastoma/pathology , Humans , Immunoenzyme Techniques , Jaw Neoplasms/pathology , Microscopy, Fluorescence , Sensitivity and Specificity
2.
Indian J Dent Res ; 24(3): 384-6, 2013.
Article in English | MEDLINE | ID: mdl-24025890

ABSTRACT

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (DLBCL/BL) is a new category of B-cell lymphoma according to the 4 th edition of the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008). The following report presents a case of this rare, newly described entity on the palate of a 59 year-old male.


Subject(s)
Burkitt Lymphoma/pathology , Lymphoma, B-Cell/pathology , Lymphoma, Large B-Cell, Diffuse/pathology , Mouth Neoplasms/pathology , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/analysis , Biopsy , Burkitt Lymphoma/drug therapy , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Humans , Lymphoma, B-Cell/drug therapy , Lymphoma, Large B-Cell, Diffuse/drug therapy , Male , Middle Aged , Mouth Neoplasms/drug therapy , Positron-Emission Tomography , Prednisone/therapeutic use , Rituximab , Tomography, X-Ray Computed , Vincristine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL